InventisBio Announces Positive Phase 2 Study Results for D-2570 (TYK2 Inhibitor) in Patients with Moderate to Severe Plaque Psoriasis
Press Releases
InventisBio Inc.  
December 3, 2024

InventisBio Announces Positive Phase 2 Study Results for D-2570 (TYK2 Inhibitor) in Patients with Moderate to Severe Plaque Psoriasis

– D-2570 demonstrates robust efficacy and favorable safety profile, achieving skin clearance comparable to leading biologics –

avatar profile Olean Times Herald

Olean Times Herald


Local & Social